Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives

ConclusionThe uptake of infliximab biosimilars has been slow at an academic medical center compared to a nearby VAMC, where financial savings are realized by the institution from its use. Slow adoption of biosimilar medications may impact the rates of decline in costs.

Source: Arthritis and Rheumatology - May 4, 2020 Category: Rheumatology Authors: Joshua F. Baker, Charles E. Leonard, Vincent Lo Re, Michael H. Weisman, Michael D. George, Jonathan Kay Tags: Brief Report Source Type: research